Dabrafenib (1)

Pharmacogenomic Information

DrugTherapeutic Area*
Labeling Sections
DabrafenibOncologyBRAFBRAF V600E/K
mutation positive
Indications and Usage,
Dosage and Administration,
Warnings and Precautions, Adverse Reactions,
Clinical Pharmacology,
Clinical Studies,
Patient Counseling Information


* Therapeutic areas do not necessarily reflect the CDER review division.

† Standard nomenclature is used for genes as per the Human Genome Organization symbol, cytogenetic abnormalities as per the International System for Human Cytogenetic Nomenclature, or other conventions.


back to Table of Pharmacogenomic Biomarkers in Drug Labeling

Page Last Updated: 03/17/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.